Microbiology and Infection · global
Uncovering Tuberculosis Bacteria’s Dual Vulnerabilities: Genetic Interaction Map Reveals Four Synergistic Drug Combinations
Two drugs used together may enhance or hinder each other’s effects. By suppressing genes in pairs, researchers narrowed the search, providing experimental leads for tuberculosis drug combinations; further validation is still needed before these findings can improve patient treatment.
Treating tuberculosis requires multiple antibiotics working together, but predicting which combinations will attack the bacteria more effectively is difficult. Researchers at Rockefeller University focused on genes that tuberculosis bacteria depend on for survival, mapping nearly 6,500 genetic interactions and identifying four synergistic drug combinations in an effort to give the search for treatments a stronger evidence base.
The study, published in *Nature*, centered on reducing the expression of two genes simultaneously. Removing essential genes outright can kill the bacteria, making further study difficult. The team therefore refined CRISPR interference (CRISPRi), which lowers gene activity without cutting DNA, then compared the effects of individual and paired gene suppression on bacterial growth.
The researchers first established the method in Mycobacterium smegmatis, then expanded the screen to 762 genes in Mycobacterium tuberculosis. If suppressing two genes simultaneously impaired growth more than expected, it suggested that the pair might represent a dual vulnerability worth investigating; drugs targeting the products of these genes might also act synergistically. However, gene suppression provides candidate directions, and drug effects still require separate testing.
According to the university’s announcement and the same research overview published on Phys.org, the team identified four synergistic drug combinations. In one, an experimental compound enhanced the bacteria-killing activity of the existing tuberculosis drug ethambutol. Another combination showed antagonism, with the two drugs interfering with each other’s effects. The map also predicted dozens of potentially synergistic combinations, but these predictions cannot be equated with validated results.
The map also provided clues about some genes with unknown functions. By comparing their interaction patterns with those of known genes, the researchers linked several genes to the electron transport chain that bacteria need to generate energy. Follow-up experiments confirmed their involvement in the function of a major respiratory protein complex. This means the research can help identify survival mechanisms that remain incompletely understood, alongside its search for drug combinations.
The team has made the interaction data publicly available for other researchers to examine and build on. The Pebble dataset page lists results for Mycobacterium tuberculosis H37Rv and Mycobacterium smegmatis mc²155 and links to the study. The co-first authors are Isaac Kresse and Natalie Sayegh, and the co-senior authors are Michael DeJesus and Jeremy Rock.
The findings remain laboratory research and cannot yet establish which combinations could shorten treatment for patients or improve treatment for drug-resistant tuberculosis. The researchers next hope to include nonessential genes and test whether these interactions change under conditions that more closely resemble infection in the human body. The map’s immediate value is to identify directions with stronger grounds for priority testing in subsequent drug development.